Keywords: oncologists, reluctant, switch, tykerb, yet, ready, use

Oncologists reluctant to switch to Tykerb

Article | 20 August 2007

Print This

Oncologists are "not yet ready" to use UK drug major GlaxoSmithKline's Tykerb (lapatinib), an oral dual kinase inhibitor therapy, as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in